<div id="readability-page-1"><p>Intuitive Surgical (NASDAQ:ISRG - Get Free Report) announced its earnings results on Thursday. The medical equipment provider reported $2.53 EPS for the quarter, beating analysts' consensus estimates of $2.25 by $0.28, FiscalAI reports. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The business had revenue of $2.87 billion during the quarter, compared to analysts' expectations of $2.72 billion.</p><div><p><span></span><span>Get <strong>Intuitive Surgical</strong> alerts:</span></p></div><h2>Intuitive Surgical Stock Up 0.3%</h2><ul><li>Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors</li></ul><p>Shares of Intuitive Surgical stock traded up $1.63 during trading on Thursday, hitting $525.32. 2,167,893 shares of the company were exchanged, compared to its average volume of 2,008,178. Intuitive Surgical has a fifty-two week low of $425.00 and a fifty-two week high of $616.00. The firm has a 50 day moving average price of $563.63 and a 200 day moving average price of $511.76. The stock has a market capitalization of $188.32 billion, a price-to-earnings ratio of 69.49, a P/E/G ratio of 4.28 and a beta of 1.67. </p><h2>Insider Activity at Intuitive Surgical</h2><p>In related news, EVP Henry L. Charlton sold 13,731 shares of the company's stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $580.00, for a total transaction of $7,963,980.00. Following the transaction, the executive vice president owned 3,056 shares of the company's stock, valued at approximately $1,772,480. This represents a 81.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO David J. Rosa sold 24,500 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $547.55, for a total value of $13,414,975.00. Following the transaction, the chief executive officer owned 234,256 shares in the company, valued at $128,266,872.80. This trade represents a 9.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 114,007 shares of company stock valued at $63,533,844 in the last ninety days. 0.70% of the stock is owned by insiders. </p><h2>Institutional Investors Weigh In On Intuitive Surgical</h2><ul><li>2 Healthcare Names That Could Get a Big Boost From Earnings</li></ul><p>A number of institutional investors have recently added to or reduced their stakes in the company. Riggs Asset Managment Co. Inc. lifted its stake in shares of  Intuitive Surgical by 84.2% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 32 shares in the last quarter.  JPL Wealth Management LLC purchased a new position in  Intuitive Surgical in the third quarter valued at approximately $45,000.  Wealth Watch Advisors INC acquired a new position in  Intuitive Surgical during the third quarter valued at approximately $52,000.  Triumph Capital Management purchased a new stake in  Intuitive Surgical during the third quarter worth approximately $54,000.  Finally, Measured Wealth Private Client Group LLC acquired a new stake in shares of  Intuitive Surgical in the third quarter worth $70,000. Hedge funds and other institutional investors own  83.64% of the company's stock. </p><h2>Intuitive Surgical News Summary</h2><p>Here are the key news stories impacting Intuitive Surgical this week:</p><ul>   <li><span>Positive Sentiment: </span>Bank of America initiated coverage with a Buy, giving investors a fresh, reputable buy-side endorsement that can lift near-term demand for the shares. <i></i><span>Intuitive Surgical (ISRG) Receives a Buy from Bank of America Securities</span></li>    <li><span>Positive Sentiment: </span>Market rotation into medtech and a bullish sector thesis highlight ISRG’s recurring-revenue model and procedure growth, supporting a multi-year growth case and analyst price targets above the current share price. <i></i><span>Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors (Intuitive Surgical section)</span></li>    <li><span>Positive Sentiment: </span>Long-term bullish analysis argues ISRG’s robotics-led growth and razor‑and‑blade recurring revenue create attractive upside over a multi-year horizon, reinforcing buy-and-hold narratives for growth investors. <i></i><span>Where Will Intuitive Surgical Be in 5 Years?</span></li>    <li><span>Neutral Sentiment: </span>Multiple earnings previews and analyst notes (TipRanks, MSN, Zacks) emphasize Q4 results and guidance as the next catalyst; these previews highlight metrics investors should watch (procedure volumes, system placements, recurring consumable growth). <i></i><span>Intuitive Surgical (ISRG) Is About to Report Q4 Earnings. Here Is What to Expect</span></li>    <li><span>Neutral Sentiment: </span>Macro headlines on weekly jobless claims are mixed and may influence broad market risk appetite (and thus medtech multiple expansion/contraction), but they don’t directly alter ISRG’s fundamentals. <i></i><span>Jobless Claims Stay Low at +200K, Q3 GDP Up to +4.4%</span></li>    <li><span>Negative Sentiment: </span>Short-term technical weakness: coverage notes and market reports point out the stock has been extending a losing streak, which can trigger stop-losses and short-term selling pressure even if fundamentals remain intact. <i></i><span>Intuitive Surgical continues losses for seven straight sessions</span></li>    <li><span>Negative Sentiment: </span>Valuation debate: commentary questioning whether ISRG is overvalued after recent weak price performance could keep some investors sidelined until clearer earnings/guidance evidence appears. <i></i><span>Assessing Whether Intuitive Surgical (ISRG) Shares Look Overvalued After Recent Weak Price Performance</span></li> </ul><h2>Wall Street Analyst Weigh In</h2><ul><li>$134M in Insider Moves: What It Might Mean for KMI, ISRG and QS</li></ul><p>A number of research analysts have recently issued reports on the company. Weiss Ratings  reissued a &#34;hold (c+)&#34; rating on shares of Intuitive Surgical in a report on Monday, December 29th. The Goldman Sachs Group  reissued a &#34;buy&#34; rating and issued a $714.00 price objective on shares of Intuitive Surgical in a research note on Friday, January 9th. Raymond James Financial  set a $603.00 price objective on shares of Intuitive Surgical and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, October 22nd. UBS Group  restated a &#34;neutral&#34; rating on shares of Intuitive Surgical in a research note on Thursday, January 15th. Finally, Truist Financial boosted their price target on shares of Intuitive Surgical from $620.00 to $650.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eight have issued  a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $622.17.</p><p><b>View Our Latest Analysis on Intuitive Surgical</b></p><h2>Intuitive Surgical Company Profile</h2> (Get Free Report)<p>Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon's hand movements into finer, scaled motions of small instruments inside the patient. Intuitive's business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.  </p><p>In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Intuitive Surgical</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li><li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li><li>New gold price target</li><li>The $100 Trillion AI Story No One Is Telling You</li><li>Trump Did WHAT??</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVNSRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVNSRw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Intuitive Surgical Right Now?</h2><p>Before you consider Intuitive Surgical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intuitive Surgical wasn't on the list.</p><p>While Intuitive Surgical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ISUL

ISRG

<p>Intuitive Surgical (NASDAQ:ISRG) reported earnings of $2.53 per share, surpassing estimates of $2.25, with quarterly revenue of $2.87 billion, exceeding expectations of $2.72 billion. The company achieved a net margin of 28.58% and a return on equity of 15.08%. Following the announcement, shares rose 0.3% to $525.32. Insider trading included significant sales by executives, and institutional investors hold 83.64% of the stock. Analysts remain positive, with Bank of America initiating coverage with a Buy rating, highlighting growth potential in the medtech sector.</p>

Intuitive Surgical (NASDAQ:ISRG) Announces Earnings Results